- Home
- GEG vs BOLD Comparison
GEG vs BOLD Comparison
Compare GEG & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEG
- BOLD
- Stock Information
- Founded
- GEG 1994
- BOLD 2018
- Country
- GEG United States
- BOLD United States
- Employees
- GEG N/A
- BOLD N/A
- Industry
- GEG Computer Software: Prepackaged Software
- BOLD
- Sector
- GEG Technology
- BOLD
- Exchange
- GEG Nasdaq
- BOLD Nasdaq
- Market Cap
- GEG 52.4M
- BOLD 54.9M
- IPO Year
- GEG N/A
- BOLD 2024
- Fundamental
- Price
- GEG $1.84
- BOLD $2.50
- Analyst Decision
- GEG
- BOLD Buy
- Analyst Count
- GEG 0
- BOLD 3
- Target Price
- GEG N/A
- BOLD $22.50
- AVG Volume (30 Days)
- GEG 55.0K
- BOLD 103.1K
- Earning Date
- GEG 02-11-2025
- BOLD 11-07-2024
- Dividend Yield
- GEG N/A
- BOLD N/A
- EPS Growth
- GEG N/A
- BOLD N/A
- EPS
- GEG N/A
- BOLD N/A
- Revenue
- GEG $18,516,000.00
- BOLD N/A
- Revenue This Year
- GEG N/A
- BOLD N/A
- Revenue Next Year
- GEG N/A
- BOLD N/A
- P/E Ratio
- GEG N/A
- BOLD N/A
- Revenue Growth
- GEG 83.09
- BOLD N/A
- 52 Week Low
- GEG $1.70
- BOLD $2.33
- 52 Week High
- GEG $2.12
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- GEG 53.59
- BOLD N/A
- Support Level
- GEG $1.76
- BOLD N/A
- Resistance Level
- GEG $1.88
- BOLD N/A
- Average True Range (ATR)
- GEG 0.03
- BOLD 0.00
- MACD
- GEG 0.00
- BOLD 0.00
- Stochastic Oscillator
- GEG 85.71
- BOLD 0.00
About GEG Great Elm Group Inc.
Great Elm Group Inc operates as an alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Along with its subsidiaries, it manages Great Elm Capital Corp, a publicly traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.